Galderma (a/k/a Nestlé Skin Health) could acquire RVNC if they returned their Dysport rights to Ipsen, which they would probably be happy to do if they could obtain a better product (i.e. RT002). Moreover, acquiring RVNC would give Galderma entry to the therapeutic side of the botulinum-toxin market, which they don’t currently have.
News 
Market Data 
Discover 
